SPY304.32+1.35 0.45%
DIA254.29-0.06 -0.02%
IXIC9,489.87+120.88 1.29%

H.C. Wainwright Maintains Buy on Aeglea BioTherapeutics, Lowers Price Target to $17

H.C. Wainwright maintains Aeglea BioTherapeutics (NASDAQ:AGLE) with a Buy and lowers the price target from $18 to $17.

Benzinga · 05/08/2020 14:45

H.C. Wainwright maintains Aeglea BioTherapeutics (NASDAQ:AGLE) with a Buy and lowers the price target from $18 to $17.